Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study

• Váldodahkkit: Ravish H S (Dahkki), Akash Khobragade (Dahkki), Durga Satapathy (Dahkki), Monica Gupta (Dahkki), Surendra Kumar (Dahkki), Vinay Bhomia (Dahkki), Ramasubramanian V (Dahkki), Maharshi Desai (Dahkki), Ashok Dilipkumar Agrawal (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2021-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background Rabies vaccines are lifesaving in human post animal exposure. However, the compliance to the complete course of vaccine is found to be only 60%. Hence, there is a need for safe and immunogenic, shorter course vaccine that can enhance the compliance and effectively prevent the disease. Obj...